Otsuka S, Yamashita J, Keyaki A, Handa H
Gan To Kagaku Ryoho. 1984 May;11(5):1084-91.
Four patients with glioblastoma and one patient with astrocytoma (grade III) were treated with recombinant IFN ( rIFN -alpha A, Ro 22-8181) and the effect of IFN on clinical symptoms, CT findings and side effects of IFN were studied. Neurological symptoms were improved in one patient, stable in one patient and worsened in three patients. In all cases, there was no remarkable change of CT findings but in one case a slight decrease in tumor size was recognized. With regards to IFN side effects general malaise, anorexia, fever, nausea and vomiting were observed clinically, decrease of leukocytes, platelets, erythrocytes, hematocrit, hemoglobin and increase of GOT, GPT, LDH, AL-P were noted in the laboratory findings. These symptoms and change in laboratory findings were not serious, and they recovered spontaneously during or after IFN therapy. In one patient, an increase in IFN neutralizing antibody titer was detected. Since the biological activity of IFN may be diminished and anti-tumor effect cannot be expected in such a patient, the appearance of IFN neutralizing antibody may indicate an important problem in IFN therapy.
4例胶质母细胞瘤患者和1例间变性星形细胞瘤（Ⅲ级）患者接受了重组干扰素（rIFN-αA，Ro 22 - 8181）治疗，并对干扰素对临床症状、CT表现及干扰素副作用的影响进行了研究。1例患者神经症状改善，1例稳定，3例恶化。所有病例中，CT表现均无显著变化，但1例患者肿瘤大小略有减小。关于干扰素副作用，临床上观察到全身不适、厌食、发热、恶心和呕吐，实验室检查发现白细胞、血小板、红细胞、血细胞比容、血红蛋白减少，谷草转氨酶、谷丙转氨酶、乳酸脱氢酶、碱性磷酸酶升高。这些症状和实验室检查结果的变化并不严重，且在干扰素治疗期间或之后自行恢复。1例患者检测到干扰素中和抗体滴度升高。由于在这类患者中干扰素的生物活性可能会降低且无法预期抗肿瘤效果，干扰素中和抗体的出现可能表明干扰素治疗中存在一个重要问题。
